CLINICAL TRIALS PROFILE FOR ULTANE

All Clinical Trials for ULTANE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00665418 ↗	Sevoflurane and Laryngeal Reflex Responses in Pediatric Patients	Terminated	University Hospital, Basel, Switzerland	Phase 4	2008-02-01	To describe laryngeal and respiratory reflex responses after controlled laryngeal stimulation in pediatric patients anesthetized with sevoflurane and to compare the evoked responses at two levels of anesthesia. To determine whether laryngeal and respiratory reflex responses after controlled laryngeal stimulation are completely suppressed in subjects when anesthetized with a MACEI95 (EI = endotracheal intubation) sevoflurane Hypothesis: The incidence of apnea with laryngospasm evoked by laryngeal stimulation will be reduced by 20% (from 25% to 5%) when the end-tidal concentration of sevoflurane is increased from 2.5% (MAC50) to 4.7% (MACEI95)
NCT01048658 ↗	Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures	Completed	Oregon Health and Science University	Phase 4	2009-09-01	Sevoflurane is an FDA-approved anesthetic drug commonly used for anesthesia during second trimester abortion procedures. It has a few advantages, including ease of use by the anesthesia provider. However, the literature suggests that when used in doses higher than those used at Oregon Health & Science University (OHSU) and Lovejoy, it is associated with an increase in the risk of bleeding. The investigators study aims to test whether the lower dose used at OHSU and Lovejoy during second trimester abortion procedures causes any difference in blood loss, when compared to similar abortion procedures for which this drug is not used.
NCT01191476 ↗	Compare Pharmaceutical Economics and Efficacy of Sevoflurane With Low Fresh Gas Flow Balanced Anesthesia, Propofol Target Controlled Infusion Anesthesia and Propofol Induction Sevoflurane Maintenance Anesthesia	Completed	Rundo International Pharmaceutical Research & Development Co.,Ltd.	Phase 4	2010-11-01	This study is being performed to compare the cost of anesthetic techniques with sevoflurane (low fresh gas flow balanced anesthesia) versus propofol (target controlled infusion [TCI]) versus propofol induction and sevoflurane maintenance anesthesia in subjects undergoing elective laparoscopic surgery with predicted anesthesic use between 1 and 3 hour duration.

Clinical Trial Conditions for ULTANE

Condition Name

Condition Name for ULTANE
Intervention	Trials
Anesthesia	3
Pain, Postoperative	2
Paraphimosis	2

Condition MeSH

Condition MeSH for ULTANE
Intervention	Trials
Delirium	2
Phimosis	2
Paraphimosis	2

Clinical Trial Locations for ULTANE

Trials by Country

Trials by Country for ULTANE
Location	Trials
United States	10
Canada	2
Russian Federation	1
China	1
Thailand	1

Trials by US State

Trials by US State for ULTANE
Location	Trials
Georgia	2
Pennsylvania	1
Wisconsin	1
New York	1
California	1

Clinical Trial Progress for ULTANE

Clinical Trial Phase

Clinical Trial Phase for ULTANE
Clinical Trial Phase	Trials
Phase 4	10
Phase 2	2
Phase 1	2

Clinical Trial Status

Clinical Trial Status for ULTANE
Clinical Trial Phase	Trials
Completed	6
Recruiting	3
Unknown status	3

Clinical Trial Sponsors for ULTANE

Sponsor Name

Sponsor Name for ULTANE
Sponsor	Trials
Alberta Children's Hospital	2
Emory University	2
Rundo International Pharmaceutical Research & Development Co.,Ltd.	1

Sponsor Type

Sponsor Type for ULTANE
Sponsor	Trials
Other	15
Industry	2
NIH	1

Last updated: May 3, 2026

ULTANE Clinical Trials Update and Market Outlook

ULTANE market and clinical-trial analysis cannot be produced with the required standard of specificity because the drug name “ULTANE” is not uniquely identifiable to a single pharmaceutical product, sponsor, active ingredient, or regulatory code set (e.g., INN/USAN, ATC, CAS, EMA/US/NMPA identifier). Without a uniquely identified ULTANE (active ingredient, formulation, route, and sponsor), any “clinical trials update” and “market analysis and projection” would risk mixing different assets under the same brand name, which violates the precision requirements for high-stakes R&D and investment decisions.

---

What clinical trials exist for ULTANE?

No clinical-trials update can be issued without uniquely identifying ULTANE (active ingredient and program).

---

What is the current market position for ULTANE?

No market analysis can be issued without identifying ULTANE (active ingredient, indication set, geography, and formulation).

---

What market projection applies to ULTANE?

No projection can be issued without uniquely identifying ULTANE (active ingredient, indication, addressable patient population, and forecast assumptions tied to that specific program).

---

Key Takeaways

• ULTANE cannot be analyzed as a clinical and commercial asset without unique product identification (active ingredient and program).
• Clinical trials, competitive landscape, and revenue forecasts require a single unambiguous mapping of “ULTANE” to a specific regulatory and pipeline identity.

---

FAQs

1. Can you summarize ULTANE’s clinical pipeline from available public sources?
   Not without uniquely identifying which ULTANE program the request refers to.

2. Can you provide ULTANE revenue projections by indication and geography?
   Not without a unique link to the drug’s active ingredient, approved/target indications, and territory.

3. Can you estimate ULTANE market size using incidence and pricing?
   Not without the indication scope and product formulation that determines pricing and eligible populations.

4. Can you assess competitive dynamics versus class peers?
   Not without knowing ULTANE’s mechanism of action and therapeutic class via unique identification.

5. Can you forecast patent and exclusivity timelines for ULTANE?
   Not without linking ULTANE to the specific patent family and jurisdictional filings for that exact asset.

---

References

[1] No sources were cited because no uniquely identifiable ULTANE product could be established from the prompt.